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The treatment of in-transit and satellite melanoma
metastases is challenging. Treatment options for these
cutaneous and subcutaneous lesions include surgical
excision, radiotherapy, isolated limb infusion/perfu-
sion, electrochemotherapy, cryotherapy, laser therapy
(pulsed dye or carbon dioxide), systemic treatment
with interferon-a or interleukin-2 (IL-2), topical
imiquimod, dinitrochlorobenzene, and intralesional
immunotherapy with bacillus Calmette-Guerin vac-
cine, granulocyte macrophage colony-stimulating
factor, IL-2, or talimogene laherparepvec.1 Response
rates for these therapies are often suboptimal. Topical
imiquimod has been used for the treatment of both
melanoma in situ (in patients who are either poor
surgical candidates or have positive margins after
excision) and in-transit metastases.1,2 There are
reports of regression of locoregional melanoma
metastases after topical imiquimod to cutaneous
lesions.1,2 Combination therapy using intralesional
IL-2 together with topical imiquimod and tretinoin
may increase the efficacy of IL-2.3 Here we report the
case of a patient with in-transit metastatic melanoma
treated with intratumoral IL-2 together with topical
imiquimod and tretinoin cream.
CASE REPORT
A 64-year-old man with a history of Crohn’s
disease and depression presented with a 1.2-cm
enlarging black nodule involving his right ear. A
biopsy found melanoma with a Breslow depth of
2 mm without mitoses or vascular invasion. He
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negative. Eight months later, the patient had a local
recurrence and underwent right ear amputation and
a second sentinel lymph node biopsy that found 1
positive lymph node. He was evaluated for systemic
therapy, but his active Crohn’s disease precluded
him from immunotherapy with ipilimumab, treat-
ment with high-dose IL-2 was contraindicated given
his history of depression with suicidal ideation, and
the tumor did not have a BRAF mutation. The patient
had recurrent disease in the auditory canal 3 months
later andwas treated with local radiation followed by
wide excision and lymph node dissection (all lymph
nodes negative). In-transit metastases developed
adjacent to the right ear surgical scar, and the patient
underwent 5 cycles of chemotherapy with carbopla-
tin and paclitaxel. The in-transit metastases
decreased in size and number over the next
3 months; 9 months later, however, more than 10
new in-transit metastases were noted at the periph-
ery of the right ear graft site (Fig 1, A).
The patient was treated with intralesional high-
dose IL-2 twice weekly (beginning at 7 million units
per treatment and increased by 2 million units
weekly) in conjunction with topical imiquimod and
tretinoin 0.1% cream applied together once daily to
all visible metastases with a 5-cm peripheral margin.
Treatment side effects were tolerable and includedJAAD Case Reports 2016;2:114-6.
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Fig 1. A, Melanoma in-transit metastases at the periphery of the right ear graft. B, Inflammatory
response after 2 weeks of treatment (4 injections of intralesional IL-2 plus topical imiquimod
and tretinoin 0.1% cream applied once daily). C, Clinical resolution of the in-transit metastases
2 months after treatment and with maintenance therapy (topical imiquimod with tretinoin 0.1%
cream daily for 7 consecutive days monthly).
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tron), and local inflammatory response. Skin ero-
sions and intense erythema were visible after
2 weeks of treatment (4 injections; Fig 1, B), and it
was decided to maintain the dose of IL-2 at 11 million
units per injection. After 5 weeks (10 injections),
there was complete resolution of all visible in-transit
metastases, and intralesional immunotherapy was
stopped. The patient was then maintained on topical
imiquimod and tretinoin 0.1% cream applied once
daily for 7 consecutive days each month (Fig 1, C ).
Two months later, there was no clinical evidence of
skin disease, and a positron emission tomography
scan was negative for metastatic disease. Nine
months after treatment, the skin remained clear, but
the patient noted lower back pain and was found to
have bony metastases and liver and pulmonary
metastases. A biopsy of the sacrum confirmed
metastatic melanoma. The patient elected comfort
care and died 10 months after completion of therapy
with intralesional IL-2.
DISCUSSION
Intralesional IL-2 may be beneficial for the treat-
ment of in-transit melanoma metastases.3-5 Earlier
studies used lower concentrations (3 and 3.6 million
units) with lower response rates (50% and 62.5%)
compared with the more recent study by Shi et al3 in
which higher-dose IL-2 (up to 22 million units)
combined with topical imiquimod and tretinoin
0.1% cream resulted in a 100% complete
response.3-5 Our case was included as a data point
in the larger series by Shi et al3 that was published
previously and highlights the efficacy and tolerability
of this therapeutic regimen. For our patient, weplanned to titrate up from 7 to 22 million units per
injection, but in the setting of a robust inflammatory
response, therapy was maintained at 11 million units
per injection. After 5 weeks of therapy, there was no
evidence of residual disease, so maintenance ther-
apy was started. As highlighted in the recent publi-
cation by Shi et al,3 11 of 11 patients (including our
case) were treated with 4 to 6 weeks of combination
therapy and achieved complete clinical response
within 1 to 3months.3 Our patient was categorized as
having smaller lesion size (\1 cm) compared with
other cases (7 of 11 patients had[1-cm lesions) and
medium number of total lesions (between 6 and 19)
compared with other cases (5 of 11 patients had[20
lesions).3 Overall, the size and number of metastatic
lesions had no effect on the clinical response.3
Each agent of the triple regimen has a distinct
mechanism. IL-2 may induce antitumoral response
via both activation of natural killer cells and CD8 and
CD4 T cells.6 Imiquimod induces antitumoral cyto-
kines including tumor necrosis factor, interferon-a,
and interleukin-12 via interaction with toll-like re-
ceptors 7 and 8.7 Topical retinoids influence kerati-
nocyte maturation and may increase epidermal
penetration of imiquimod, resulting in an enhanced
inflammatory response.8 A randomized study of 90
patients with lentigo maligna found an increased
likelihood of achieving a robust inflammatory
response with combination tazarotene gel and imi-
quimod cream (80%) versus imiquimod cream alone
(60%).8
Although new targeted therapies have revolution-
ized the way advanced melanoma is treated, intrale-
sional immunotherapy may have a role in treating
patients with multiple comorbidities and poor
JAAD CASE REPORTS
MARCH 2016
116 Leventhal et alfunctional status and patients with contraindications
to systemic immunotherapy or who have not re-
sponded to targeted therapy or chemotherapy.
Intralesional IL-2 is also appealing for the manage-
ment of patients with disease limited to in-transit
metastases or local recurrences. Mid- to high-dose
intralesional IL-2 combined with topical imiquimod
and tretinoin cream should be considered for the
management of cutaneous melanoma metastases.
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